LG-631 is under clinical development by Lentigen Technology and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs for Gliosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LG-631 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LG-631 overview
LG-631 is under development for the treatment of glioblastoma multiforme and gliosarcoma. It is administered through intravenous route. It is developed based on lentiviral gene delivery technology. The therapeutic candidate consists adult hematopoietic stem cells genetically modified with a lentiviral vector expressing a human P140K methylguanine methyltransferase gene variant. It was also under development for the treatment of for the protection of hematopoietic stem cells from the dose limiting toxicity of chemotherapy.
Lentigen Technology overview
Lentigen Technology (Lentigen), a subsidiary of Miltenyi Biotec GmbH, is a provider of gene delivery and expression technology solutions. The company provides clinical trial support in viral vector product development and clinical applications, among others. Its lentiviral vectors finds application in the T cell and hematopoietic stem cell transduction. Lentigen also offers contract manufacturing programs for the production of lentiviral vector products. The company works in partnership with other organizations for the lentiviral vector development and manufacturing. Lentigen is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of LG-631’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
